Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy

Standard

Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. / Grint, D; Peters, L; Reekie, J; Soriano, V; Kirk, O; Knysz, B; Suetnov, O; Lazzarin, A; Ledergerber, B; Rockstroh, J K; Mocroft, A; EuroSIDA in EuroCoord.

In: HIV MED, Vol. 14, No. 6, 01.07.2013, p. 370-8.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Grint, D, Peters, L, Reekie, J, Soriano, V, Kirk, O, Knysz, B, Suetnov, O, Lazzarin, A, Ledergerber, B, Rockstroh, JK, Mocroft, A & EuroSIDA in EuroCoord 2013, 'Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy', HIV MED, vol. 14, no. 6, pp. 370-8. https://doi.org/10.1111/hiv.12033

APA

Grint, D., Peters, L., Reekie, J., Soriano, V., Kirk, O., Knysz, B., Suetnov, O., Lazzarin, A., Ledergerber, B., Rockstroh, J. K., Mocroft, A., & EuroSIDA in EuroCoord (2013). Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV MED, 14(6), 370-8. https://doi.org/10.1111/hiv.12033

Vancouver

Bibtex

@article{fa9e28f39d174e3d9bcaeccb7fa0ed38,
title = "Stability of hepatitis C virus (HCV) RNA levels among interferon-na{\"i}ve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy",
abstract = "OBJECTIVES: Infection with hepatitis C virus (HCV) is a major cause of chronic liver disease. High HCV RNA levels have been associated with poor treatment response. This study aimed to examine the natural history of HCV RNA in chronically HCV/HIV-coinfected individuals.METHODS: Mixed models were used to analyse the natural history of HCV RNA changes over time in HIV-positive patients with chronic HCV infection.RESULTS: A total of 1541 individuals, predominantly White (91%), male (73%), from southern (35%) and western central Europe (23%) and with HCV genotype 1 (58%), were included in the analysis. The median follow-up time was 5.0 years [interquartile range (IQR) 2.8 to 8.3 years]. Among patients not on combination antiretroviral therapy (cART), HCV RNA levels increased by a mean 27.6% per year [95% confidence interval (CI) 6.1-53.5%; P = 0.0098]. Among patients receiving cART, HCV RNA levels were stable, increasing by a mean 2.6% per year (95% CI -1.1 to 6.5%; P = 0.17). Baseline HCV RNA levels were 25.5% higher (95% CI 8.8 to 39.1%; P = 0.0044) in individuals with HCV genotype 1 compared with HCV genotypes 2, 3 and 4. A 1 log HIV-1 RNA copies/mL increase in HIV RNA was associated with a 10.9% increase (95% CI 2.3 to 20.2%; P = 0.012) in HCV RNA.CONCLUSIONS: While HCV RNA levels increased significantly in patients prior to receiving cART, among those treated with cART HCV RNA levels remained stable over time.",
keywords = "Adult, Anti-Retroviral Agents, Antiretroviral Therapy, Highly Active, Cohort Studies, Europe, Female, HIV Infections, Hepacivirus, Hepatitis C, Chronic, Humans, Male, Prospective Studies, RNA, Viral, Viral Load",
author = "D Grint and L Peters and J Reekie and V Soriano and O Kirk and B Knysz and O Suetnov and A Lazzarin and B Ledergerber and Rockstroh, {J K} and A Mocroft and {EuroSIDA in EuroCoord} and {van Lunzen}, Jan",
note = "{\textcopyright} 2013 British HIV Association.",
year = "2013",
month = jul,
day = "1",
doi = "10.1111/hiv.12033",
language = "English",
volume = "14",
pages = "370--8",
journal = "HIV MED",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy

AU - Grint, D

AU - Peters, L

AU - Reekie, J

AU - Soriano, V

AU - Kirk, O

AU - Knysz, B

AU - Suetnov, O

AU - Lazzarin, A

AU - Ledergerber, B

AU - Rockstroh, J K

AU - Mocroft, A

AU - EuroSIDA in EuroCoord

AU - van Lunzen, Jan

N1 - © 2013 British HIV Association.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - OBJECTIVES: Infection with hepatitis C virus (HCV) is a major cause of chronic liver disease. High HCV RNA levels have been associated with poor treatment response. This study aimed to examine the natural history of HCV RNA in chronically HCV/HIV-coinfected individuals.METHODS: Mixed models were used to analyse the natural history of HCV RNA changes over time in HIV-positive patients with chronic HCV infection.RESULTS: A total of 1541 individuals, predominantly White (91%), male (73%), from southern (35%) and western central Europe (23%) and with HCV genotype 1 (58%), were included in the analysis. The median follow-up time was 5.0 years [interquartile range (IQR) 2.8 to 8.3 years]. Among patients not on combination antiretroviral therapy (cART), HCV RNA levels increased by a mean 27.6% per year [95% confidence interval (CI) 6.1-53.5%; P = 0.0098]. Among patients receiving cART, HCV RNA levels were stable, increasing by a mean 2.6% per year (95% CI -1.1 to 6.5%; P = 0.17). Baseline HCV RNA levels were 25.5% higher (95% CI 8.8 to 39.1%; P = 0.0044) in individuals with HCV genotype 1 compared with HCV genotypes 2, 3 and 4. A 1 log HIV-1 RNA copies/mL increase in HIV RNA was associated with a 10.9% increase (95% CI 2.3 to 20.2%; P = 0.012) in HCV RNA.CONCLUSIONS: While HCV RNA levels increased significantly in patients prior to receiving cART, among those treated with cART HCV RNA levels remained stable over time.

AB - OBJECTIVES: Infection with hepatitis C virus (HCV) is a major cause of chronic liver disease. High HCV RNA levels have been associated with poor treatment response. This study aimed to examine the natural history of HCV RNA in chronically HCV/HIV-coinfected individuals.METHODS: Mixed models were used to analyse the natural history of HCV RNA changes over time in HIV-positive patients with chronic HCV infection.RESULTS: A total of 1541 individuals, predominantly White (91%), male (73%), from southern (35%) and western central Europe (23%) and with HCV genotype 1 (58%), were included in the analysis. The median follow-up time was 5.0 years [interquartile range (IQR) 2.8 to 8.3 years]. Among patients not on combination antiretroviral therapy (cART), HCV RNA levels increased by a mean 27.6% per year [95% confidence interval (CI) 6.1-53.5%; P = 0.0098]. Among patients receiving cART, HCV RNA levels were stable, increasing by a mean 2.6% per year (95% CI -1.1 to 6.5%; P = 0.17). Baseline HCV RNA levels were 25.5% higher (95% CI 8.8 to 39.1%; P = 0.0044) in individuals with HCV genotype 1 compared with HCV genotypes 2, 3 and 4. A 1 log HIV-1 RNA copies/mL increase in HIV RNA was associated with a 10.9% increase (95% CI 2.3 to 20.2%; P = 0.012) in HCV RNA.CONCLUSIONS: While HCV RNA levels increased significantly in patients prior to receiving cART, among those treated with cART HCV RNA levels remained stable over time.

KW - Adult

KW - Anti-Retroviral Agents

KW - Antiretroviral Therapy, Highly Active

KW - Cohort Studies

KW - Europe

KW - Female

KW - HIV Infections

KW - Hepacivirus

KW - Hepatitis C, Chronic

KW - Humans

KW - Male

KW - Prospective Studies

KW - RNA, Viral

KW - Viral Load

U2 - 10.1111/hiv.12033

DO - 10.1111/hiv.12033

M3 - SCORING: Journal article

C2 - 23534815

VL - 14

SP - 370

EP - 378

JO - HIV MED

JF - HIV MED

SN - 1464-2662

IS - 6

ER -